Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Apr 11;16(4):e254742.
doi: 10.1136/bcr-2023-254742.

Laryngeal tuberculosis in patients treated with adalimumab: a casual or causal connection?

Affiliations
Case Reports

Laryngeal tuberculosis in patients treated with adalimumab: a casual or causal connection?

Giulia Molinari et al. BMJ Case Rep. .

Abstract

This article presents two consecutive cases of laryngeal tuberculosis in patients treated with a specific anti-tumour necrosis factor-alpha (adalimumab), with a focus on their diagnostic process and therapeutic management. Both patients presented with aspecific chronic laryngeal symptoms that had been worsening for a few months in one case and for almost 1 year in the other one. They were both studied with fibreoptic laryngoscopy and contrast-enhanced CT and MRI scans. In both cases, the laryngeal biopsy proved negative to Ziehl-Neelsen test, while positive to Koch's bacillus sensitive to rifampicin at PCR test. Both patients completely responded to standard antitubercular antibiotic therapy with rifampicin, isoniazid, pyrazinamide and etambutol protocol.In the differential diagnosis of such patients, laryngeal tuberculosis should be considered due to the reasonable linkage between the immunosuppressant therapy with adalimumab and the tuberculosis infection/reactivation.

Keywords: Drugs and medicines; Ear, nose and throat; Ear, nose and throat/otolaryngology; Infections.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
(A, B) Fibereoptic endoscopic appearance of case #1 at time of ear, nose and throat evaluation. Notice the ulcerated and granulomatous aspect of the epiglottis, aryepiglottic folds and arytenoids. These structures appear enlarged and swollen.
Figure 2
Figure 2
Contrast-enhanced CT of the neck from case 1. Axial view showing enhancing irregular tissue affecting both vocal folds (A) and the supraglottis (B), without relevant reduction of the airway lumen. Multiple enlarged fusiform lymph nodes are present at both cervical sides. (C) Multiple bilateral pulmonary micronodules with typical miliariform spreading can be seen. No cavitated lesions are present.
Figure 3
Figure 3
Follow-up fibreoptic image after 1 month of antitubercular medical therapy from case 1 showing improvement of the patient’s condition.
Figure 4
Figure 4
Endoscopic and radiological appearance of the larynx from case 2. (A) A swollen aspect of the epiglottis and the aryepiglottic folds and arytenoids is visible on fibreoptic examination. (B) Contrast-enhanced CT scan of the neck showing vivid contrast enhancement of the base of the tongue, lingual surface of the epiglottis and right aryepiglottic region.

References

    1. Migliorelli A, Mazzocco T, Bonsembiante A, et al. . Laryngeal tubercolosis: A case report with focus on voice assessment and review of the literature. Acta Otorhinolaryngol Ital 2022;42:407–14. 10.14639/0392-100x-n2091 - DOI - PMC - PubMed
    1. Nogueira M, Warren RB, Torres T. Risk of tuberculosis reactivation with interleukin (IL) ‐17 and IL‐23 inhibitors in psoriasis – time for a paradigm change. J Eur Acad Dermatol Venereol 2021;35:824–34. 10.1111/jdv.16866 - DOI - PubMed
    1. Brett K, Dulong C, Severn M. Treatment of tuberculosis: A review of guidelines (ON): canadian agency for drugs and technologies in health; 2020 [cited 7 february 2022]. (CADTH rapid response reports) Internet. Ottawa, Available: http://www.ncbi.nlm.nih.gov/books/NBK562947/ - PubMed
    1. Robert M, Miossec P. Reactivation of latent tuberculosis with TNF inhibitors: critical role of the beta 2 chain of the IL-12 receptor. Cell Mol Immunol 2021;18:1644–51. 10.1038/s41423-021-00694-9 - DOI - PMC - PubMed
    1. Xie X, Li F, Chen JW, et al. . Risk of tuberculosis infection in anti-TNF-α biological therapy: from bench to bedside. Journal of Microbiology, Immunology and Infection 2014;47:268–74. 10.1016/j.jmii.2013.03.005 - DOI - PubMed

Publication types

MeSH terms